Discovery of a Functional Covalent Ligand Targeting an Intrinsically Disordered Cysteine within MYC
Open accessAbstract
MYC is a major oncogenic transcriptional driver of most human cancers that has remained intractable to direct targeting because much of MYC is intrinsically disordered. Here, we have performed a cysteine-reactive covalent ligand screen to identify compounds that could disrupt the binding of MYC to its DNA consensus sequence in vitro and also impair MYC transcriptional activity in situ in cells. We have identified a covalent ligand, EN4, that targets cysteine 171 of MYC within a predicted intrinsically disordered region of the protein. We show that EN4 directly targets MYC in cells, reduces MYC and MAX thermal stability, inhibits MYC transcriptional activity, downregulates multiple MYC transcriptional targets, and impairs tumorigenesis. We also show initial structure-activity relationships of EN4 and identify compounds that show improved potency. Overall, we identify a unique ligandable site within an intrinsically disordered region of MYC that leads to inhibition of MYC transcriptional activity.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Pairing ABPP with a MYC transcription factor activity assay identified EN4 as a covalent MYC ligand.
“ABPP was paired with a MYC transcription factor activity assay to identify a covalent MYC ligand, EN4 (ref.179).”
From Advances in covalent drug discovery (2022) · cites this paper as [179]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
NIH Image to ImageJ: 25 years of image analysis
Schneider, C. A., Rasband, W. S., & Eliceiri, K. W. (2012) · Nature Methods · doi:10.1038/nmeth.2089 · Cited by 64,638 · see citing works
Salmon provides fast and bias-aware quantification of transcript expression
Patro, R., Duggal, G., Love, M. I., Irizarry, R. A., & Kingsford, C. (2017) · Nature Methods · doi:10.1038/nmeth.4197 · Cited by 12,700 · see citing works
Karin, M., Liu, Z.-G., & Zandi, E. (1997) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(97)80068-3 · Cited by 2,904 · see citing works
Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay
Molina, D. M., Jafari, R., Ignatushchenko, M., Seki, T., Larsson, E. A., Dan, C., Sreekumar, L., Cao, Y., & Nordlund, P. (2013) · Science · doi:10.1126/science.1233606 · Cited by 2,261 · see citing works
Quantitative reactivity profiling predicts functional cysteines in proteomes
Weerapana, E., Wang, C., Simon, G. M., Richter, F., Khare, S., Dillon, M. B. D., Bachovchin, D. A., Mowen, K., Baker, D., & Cravatt, B. F. (2010) · Nature · doi:10.1038/nature09472 · Cited by 1,684 · see citing works
Reflecting on 25 years with MYC
Meyer, N., & Penn, L. Z. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2231 · Cited by 1,575 · see citing works
Proteome-wide covalent ligand discovery in native biological systems
Backus, K. M., Correia, B. E., Lum, K. M., Forli, S., Horning, B. D., González-Páez, G. E., Chatterjee, S., Lanning, B. R., Teijaro, J. R., Olson, A. J., et al. (2016) · Nature · doi:10.1038/nature18002 · Cited by 940 · see citing works
Drugging the ‘undruggable’ cancer targets
Dang, C. V., Reddy, E. P., Shokat, K. M., & Soucek, L. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.36 · Cited by 927 · see citing works
Targeting oncogenic Myc as a strategy for cancer treatment
Chen, H., Liu, H., & Qing, G. (2018) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-018-0008-7 · Cited by 806 · see citing works
MYC: Connecting selective transcriptional control to global RNA production
Kress, T. R., Sabò, A., & Amati, B. (2015) · Nature reviews. Cancer · doi:10.1038/nrc3984 · Cited by 521 · see citing works
ProLuCID: An improved SEQUEST-like algorithm with enhanced sensitivity and specificity
Xu, T., Park, S. K., Venable, J. D., Wohlschlegel, J. A., Diedrich, J. K., Cociorva, D., Lu, B., Liao, L., Hewel, J., Han, X., et al. (2015) · Journal of Proteomics · doi:10.1016/j.jprot.2015.07.001 · Cited by 511 · see citing works
Zeller, K. I., Jegga, A. G., Aronow, B. J., O’Donnell, K. A., & Dang, C. V. (2003) · Genome biology · doi:10.1186/gb-2003-4-10-r69 · Cited by 483 · see citing works
Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy
Han, H., Jain, A. D., Truica, M. I., Izquierdo-Ferrer, J., Anker, J. F., Lysy, B., Sagar, V., Luan, Y., Chalmers, Z. R., Unno, K., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.10.001 · Cited by 461 · see citing works
Harnessing the anti-cancer natural product nimbolide for targeted protein degradation
Spradlin, J. N., Hu, X., Ward, C. C., Brittain, S. M., Jones, M. D., Ou, L., To, M., Proudfoot, A., Ornelas, E., Woldegiorgis, M., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0304-8 · Cited by 432 · see citing works
Self-citationXu, J., Chen, Y., & Olopade, O. I. (2010) · Genes & Cancer · doi:10.1177/1947601910378691 · Cited by 384 · see citing works
MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition
Horiuchi, D., Kusdra, L., Huskey, N. E., Chandriani, S. J., Lenburg, M. E., Gonzalez-Angulo, A. M., Creasman, K. J., Bazarov, A. V., Smyth, J. W., Davis, S., et al. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem.20111512 · Cited by 377 · see citing works
Amati, B. B. (1998) · Frontiers in bioscience · doi:10.2741/a239 · Cited by 367 · see citing works
A Quantitative Model of Thermal Stabilization and Destabilization of Proteins by Ligands
Cimmperman, P., Baranauskienė, L., Jachimovičiūtė, S., Jachno, J., Torresan, J., Michailovienė, V., Matulienė, J., Sereikaitė, J., Bumelis, V. A., & Matulis, D. (2008) · Biophysical Journal · doi:10.1529/biophysj.108.134973 · Cited by 354 · see citing works
Ward, C. C., Kleinman, J. I., Brittain, S. M., Lee, P. S., Chung, C. Y. S., Kim, K., Petri, Y., Thomas, J. R., Tallarico, J. A., McKenna, J. M., et al. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.8b01083 · Cited by 336 · see citing works
Self-citationRapid Covalent-Probe Discovery by Electrophile-Fragment Screening
Resnick, E., Bradley, A., Gan, J., Douangamath, A., Krojer, T., Sethi, R., Geurink, P. P., Aimon, A., Amitai, G., Bellini, D., et al. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b02822 · Cited by 335 · see citing works
Berg, T., Cohen, S. B., Desharnais, J., Sonderegger, C. K., Maslyar, D. J., Goldberg, J., Boger, D. L., & Vogt, P. K. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.062036999 · Cited by 326 · see citing works
Strategies to Inhibit Myc and Their Clinical Applicability
Whitfield, J. R., Beaulieu, M.-È., & Soucek, L. (2017) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00010 · Cited by 295 · see citing works
Therapeutic Strategies to Inhibit MYCPreprint
McKeown, M. R., & Bradner, J. E. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014266 · Cited by 226 · see citing works
Conacci‐Sorrell, M., Ngouenet, C., & Eisenman, R. N. (2010) · Cell · doi:10.1016/j.cell.2010.06.037 · Cited by 219 · see citing works
Carcinoma and stromal enzyme activity profiles associated with breast tumor growth in vivo
Jessani, N., Humphrey, M., McDonald, W. H., Niessen, S., Masuda, K. R., Gangadharan, B., Yates, J. R., Mueller, B. M., & Cravatt, B. F. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404727101 · Cited by 181 · see citing works
MYC regulation of a “poor-prognosis” metastatic cancer cell state
Wolfer, A., Wittner, B. S., Irimia, D., Flavin, R., Lupien, M., Gunawardane, R. N., Meyer, C. A., Lightcap, E. S., Tamayo, P., Mesirov, J. P., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914203107 · Cited by 176 · see citing works
Covalent Targeting of the Vacuolar H+-ATPase Activates Autophagy Via mTORC1 Inhibition
Chung, C., Shin, H. R., Berdan, C. A., Ford, B., Ward, C. C., Olzmann, J. A., Zoncu, R., & Nomura, D. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0308-4 · Cited by 173 · see citing works
Self-citationLINCS Data Portal 2.0: next generation access point for perturbation-response signatures
Stathias, V., Turner, J., Koleti, A., Vidovic, D., Cooper, D., Fazel-Najafabadi, M., Pilarczyk, M., Terryn, R., Chung, C., Umeano, A., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkz1023 · Cited by 161 · see citing works
Taming of the beast: shaping Myc-dependent amplification
Wolf, E., Lin, C. Y., Eilers, M., & Levens, D. (2014) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.10.006 · Cited by 135 · see citing works
Stabilization of the Max Homodimer with a Small Molecule Attenuates Myc-Driven Transcription
Struntz, N. B., Chen, A., Deutzmann, A., Wilson, R. M., Stefan, E., Evans, H. L., Ramirez, M. A., Liang, T., Caballero, F., Wildschut, M. H. E., et al. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2019.02.009 · Cited by 130 · see citing works
Covalent Ligand Discovery against Druggable Hotspots Targeted by Anti-cancer Natural Products
Grossman, E. A., Ward, C. C., Spradlin, J. N., Bateman, L. A., Huffman, T. R., Miyamoto, D. K., Kleinman, J. I., & Nomura, D. K. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.08.013 · Cited by 124 · see citing works
Self-citationMYC Modulation around the CDK2/p27/SKP2 Axis
Hydbring, P., Castell, A., & Larsson, L. (2017) · Genes · doi:10.3390/genes8070174 · Cited by 90 · see citing works
Cell cycle: On target with Myc
Zörnig, M., & Evan, G. I. (1996) · Current Biology · doi:10.1016/s0960-9822(02)70769-0 · Cited by 80 · see citing works
Bateman, L. A., Nguyen, T., Roberts, A. M., Miyamoto, D. K., Ku, W.-M., Huffman, T. R., Petri, Y. D., Heslin, M. J., Contreras, C. M., Skibola, C. F., et al. (2017) · Chemical Communications · doi:10.1039/c7cc01480e · Cited by 73 · see citing works
Self-citationRepurposing MYC and E2F in the absence of RB
Osório, J. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm4044 · Cited by 9 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- Ward CC, Kleinman JI, Brittain SM, Lee PS, Chung CYS, Kim K, Petri Y, Thomas JR, Tallarico JA, McKenna JM, (2019b). Covalent Ligand Screening Uncovers a RNF4 E3 Ligase Recruiter for Targeted Protein Degradation Applications. ACS Chem. Biol 14, 2430– 2440. 31059647 PMC7422721
Cited by
Sorted by citations
The MYC oncogene — the grand orchestrator of cancer growth and immune evasion
Dhanasekaran, R., Deutzmann, A., Mahauad‐Fernandez, W. D., Hansen, A. S., Gouw, A. M., & Felsher, D. W. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00549-2 · Cited by 1,010 · see citing works
Advances in covalent drug discovery
Boike, L., Henning, N. J., & Nomura, D. K. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00542-z · Cited by 823 · see citing works
Self-citationAdvances in Targeting ‘Undruggable’ transcription Factors With Small Molecules
Henley, M. J., & Koehler, A. N. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00199-0 · Cited by 409 · see citing works
Modulating biomolecular condensates: a novel approach to drug discovery
Mitrea, D. M., Mittasch, M., Gomes, B. F., Klein, I. A., & Murcko, M. A. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00505-4 · Cited by 408 · see citing works
Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc
Madden, S. K., de Araujo, A. D., Gerhardt, M., Fairlie, D. P., & Mason, J. M. (2021) · Molecular Cancer · doi:10.1186/s12943-020-01291-6 · Cited by 404 · see citing works
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396 · see citing works
The emerging role of mass spectrometry-based proteomics in drug discovery
Meissner, F., Geddes‐McAlister, J., Mann, M., & Bantscheff, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00409-3 · Cited by 355 · see citing works
Deubiquitinase-targeting chimeras for targeted protein stabilization
Henning, N. J., Boike, L., Spradlin, J. N., Ward, C. C., Liu, G., Zhang, E., Belcher, B. P., Brittain, S. M., Hesse, M. J., Dovala, D., et al. (2022) · Nature Chemical Biology · doi:10.1038/s41589-022-00971-2 · Cited by 344 · see citing works
Self-citationBond, M. J., & Crews, C. M. (2021) · RSC Chemical Biology · doi:10.1039/d1cb00011j · Cited by 227 · see citing works
Discovery of a Covalent FEM1B Recruiter for Targeted Protein Degradation Applications
Henning, N. J., Manford, A. G., Spradlin, J. N., Brittain, S. M., Zhang, E., McKenna, J. M., Tallarico, J. A., Schirle, M., Rape, M., & Nomura, D. K. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.1c03980 · Cited by 221 · see citing works
Self-citationMYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies
Ahmadi, S. E., Rahimi, S., Zarandi, B., Chegeni, R., & Safa, M. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01111-4 · Cited by 211 · see citing works
Reimagining Druggability Using Chemoproteomic Platforms
Spradlin, J. N., Zhang, E., & Nomura, D. K. (2021) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00065 · Cited by 176 · see citing works
Self-citationDisProt in 2022: improved quality and accessibility of protein intrinsic disorder annotation
Quaglia, F., Mészáros, B., Salladini, E., Hatos, A., Pancsa, R., Chemes, L. B., Pajkos, M., Lázár, T., Peña‐Díaz, S., Santos, J., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab1082 · Cited by 157 · see citing works
Expanding the arsenal of E3 ubiquitin ligases for proximity-induced protein degradation
Kannt, A., & Đikić, I. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.04.007 · Cited by 148 · see citing works
Ligandability of E3 Ligases for Targeted Protein Degradation Applications
Belcher, B. P., Ward, C. C., & Nomura, D. K. (2023) · Biochemistry · doi:10.1021/acs.biochem.1c00464 · Cited by 132 · see citing works
Self-citationIntrinsically disordered proteins and biomolecular condensates as drug targets
Biesaga, M., Frigolé-Vivas, M., & Salvatella, X. (2021) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2021.02.009 · Cited by 115 · see citing works
Expanding Chemical Probe Space: Quality Criteria for Covalent and Degrader Probes
Hartung, I. V., Rudolph, J., Mader, M. M., Mulder, M. P. C., & Workman, P. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00550 · Cited by 109 · see citing works
MYC in cancer: from undruggable target to clinical trials
Whitfield, J. R., & Soucek, L. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01143-2 · Cited by 106 · see citing works
MYC function and regulation in physiological perspective
Jha, R., Kouzine, F., & Levens, D. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1268275 · Cited by 106 · see citing works
MYC and therapy resistance in cancer: risks and opportunities
Donati, G., & Amati, B. B. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13319 · Cited by 99 · see citing works
Progress and Challenges in Targeted Protein Degradation for Neurodegenerative Disease Therapy
Fang, Y., Wang, J., Zhao, M., Zheng, Q., Ren, C., Wang, Y., & Zhang, J. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00844 · Cited by 100 · see citing works
The long journey to bring a Myc inhibitor to the clinic
Whitfield, J. R., & Soucek, L. (2021) · The Journal of Cell Biology · doi:10.1083/jcb.202103090 · Cited by 97 · see citing works
Targeting MYCN in Pediatric and Adult Cancers
Liu, Z., Chen, S. S., Clarke, S., Veschi, V., & Thiele, C. J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.623679 · Cited by 94 · see citing works
Interaction modules that impart specificity to disordered protein
Čermáková, K., & Hodges, H. C. (2023) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2023.01.004 · Cited by 92 · see citing works
Targeting NRF2 to treat cancer
Sivinski, J., Zhang, D. D., & Chapman, E. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.06.003 · Cited by 90 · see citing works
Ligand discovery by activity-based protein profiling
Niphakis, M. J., & Cravatt, B. F. (2024) · Cell chemical biology · doi:10.1016/j.chembiol.2024.08.006 · Cited by 90 · see citing works
Transcriptional condensates: a blessing or a curse for gene regulation?
Stortz, M., Presman, D. M., & Levi, V. (2024) · Communications Biology · doi:10.1038/s42003-024-05892-5 · Cited by 73 · see citing works
MYC-driven synthesis of Siglec ligands is a glycoimmune checkpoint
Smith, B. A. H., Deutzmann, A., Correa, K. M., Delaveris, C. S., Dhanasekaran, R., Dove, C. G., Sullivan, D. K., Wisnovsky, S., Stark, J. C., Pluvinage, J. V., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2215376120 · Cited by 73 · see citing works
Targeted Covalent Modification Strategies for Drugging the Undruggable Targets
Tamura, T., Kawano, M., & Hamachi, I. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00745 · Cited by 71 · see citing works
Computer-Aided Drug Discovery for Undruggable Targets
Sun, Q., Wang, H., Xie, J., Wang, L., Mu, J., Li, J., Ren, Y., & Lai, L. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00969 · Cited by 69 · see citing works
Holmes, A. G., Parker, J. B., Sagar, V., Truica, M. I., Soni, P. N., Han, H., Schiltz, G. E., Abdulkadir, S. A., & Chakravarti, D. (2022) · Science Advances · doi:10.1126/sciadv.abh3635 · Cited by 61 · see citing works
Multi-tiered chemical proteomic maps of tryptoline acrylamide–protein interactions in cancer cells
Njomen, E., Hayward, R. E., DeMeester, K. E., Ogasawara, D., Dix, M. M., Nguyen, T., Ashby, P., Simon, G. M., Schreiber, S. L., Melillo, B. N., et al. (2024) · Nature Chemistry · doi:10.1038/s41557-024-01601-1 · Cited by 65 · see citing works
Functionalized Scout Fragments for Site-Specific Covalent Ligand Discovery and Optimization
Crowley, V. M., Thielert, M., & Cravatt, B. F. (2021) · ACS Central Science · doi:10.1021/acscentsci.0c01336 · Cited by 53 · see citing works
Antitumor Effect of Anti‐c‐Myc Aptamer‐Based PROTAC for Degradation of the c‐Myc Protein
Wang, Y., Yang, G., Zhang, X., Bai, R., Yuan, D., Gao, D., He, Q., Yuan, Y., Zhang, X., Kou, J., et al. (2024) · Advanced Science · doi:10.1002/advs.202309639 · Cited by 51 · see citing works
Demystifying the Druggability of the MYC Family of Oncogenes
Karadkhelkar, N. M., Lin, M., Eubanks, L. M., & Janda, K. D. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.2c12732 · Cited by 50 · see citing works
Super-enhancers complexes zoom in transcription in cancer
Wang, M., Chen, Q., Wang, S., Xie, H., Liu, J., Huang, R., Xiang, Y., Jiang, Y., Tian, D., & Bian, E. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02763-5 · Cited by 49 · see citing works
Redirecting the pioneering function of FOXA1 with covalent small molecules
Won, S. J., Zhang, Y., Reinhardt, C. J., Hargis, L. M., MacRae, N. S., DeMeester, K. E., Njomen, E., Remsberg, J. R., Melillo, B. N., Cravatt, B. F., et al. (2024) · Molecular Cell · doi:10.1016/j.molcel.2024.09.024 · Cited by 43 · see citing works
Pei, H., Guo, W., Peng, Y., Xiong, H., & Chen, Y. (2022) · Medicinal Research Reviews · doi:10.1002/med.21886 · Cited by 45 · see citing works
Targeting protein disorder: the next hurdle in drug discovery
Lázár, T., Connor, A., DeLisle, C. F., Burger, V., & Tompa, P. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01220-6 · Cited by 43 · see citing works
Rational drug design targeting intrinsically disordered proteins
Wang, H., Xiong, R., & Lai, L. (2023) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.1685 · Cited by 39 · see citing works
Emerging Trends in Cancer Drug Discovery—From Drugging the “Undruggable” to Overcoming Resistance
Rudolph, J., Settleman, J., & Malek, S. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0260 · Cited by 38 · see citing works
Pomplun, S. J., Jbara, M., Schissel, C. K., Hawken, S. W., Boija, A., Li, C. H., Klein, I. A., & Pentelute, B. L. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c00663 · Cited by 37 · see citing works
The DUBA-SLC7A11-c-Myc Axis is Critical for Stemness and Ferroptosis
Wang, Z., Ouyang, L., Liu, N., Li, T., Yan, B., Mao, C., Xiao, D., Gan, B., Liu, S., & Tao, Y. (2022) · Oncogene · doi:10.1038/s41388-023-02744-0 · Cited by 36 · see citing works
Xie, T., Danieli‐Mackay, A., Buccarelli, M., Barbieri, M., Papadionysiou, I., D’Alessandris, Q. G., Robens, C., Übelmesser, N., Vinchure, O. S., Lauretti, L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48053-2 · Cited by 36 · see citing works
Qin, C., Wang, Y., Zheng, J., Wan, X., & Fan, X. (2025) · BMC Biology · doi:10.1186/s12915-025-02214-x · Cited by 39 · see citing works
Koo, T.-Y., Lai, H., Nomura, D. K., & Chung, C. Y. (2023) · Nature Communications · doi:10.1038/s41467-023-39268-w · Cited by 32 · see citing works
Self-citationPAX3-FOXO1 uses its activation domain to recruit CBP/P300 and shape RNA Pol2 cluster distribution
Asante, Y., Benischke, K., Osman, I., Ngo, Q., Wurth, J., Laubscher, D., Kim, H., Udhayakumar, B., Khan, M. I. H., Chin, D. H., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43780-4 · Cited by 31 · see citing works
Methylarginine targeting chimeras for lysosomal degradation of intracellular proteins
Seabrook, L. J., Franco, C. N., Loy, C. A., Osman, J. M., Fredlender, C., Zimak, J., Campos, M., Nguyen, S. T., Watson, R. L., Levine, S. R., et al. (2024) · Nature Chemical Biology · doi:10.1038/s41589-024-01741-y · Cited by 32 · see citing works
MYC Ran Up the Clock: The Complex Interplay between MYC and the Molecular Circadian Clock in Cancer
Burchett, J. B., Knudsen-Clark, A. M., & Altman, B. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147761 · Cited by 31 · see citing works
MYC-Targeting Inhibitors Generated from a Stereodiversified Bicyclic Peptide Library
Li, Z., Huang, Y., Hung, T. I., Sun, J., Aispuro, D., Chen, B., Guevara, N., Ji, F., Xu, C., Zhu, L., et al. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.3c09615 · Cited by 28 · see citing works
Covalent Degrader of the Oncogenic Transcription Factor β-Catenin
Gowans, F. A., Forte, N., Hatcher, J., Huang, O. W., Wang, Y., Poblano, B. E. A., Wertz, I. E., & Nomura, D. K. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c05174 · Cited by 28 · see citing works
Self-citationJuillerat‐Jeanneret, L., Tafelmeyer, P., & Golshayan, D. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01010 · Cited by 26 · see citing works
Drugging Fuzzy Complexes in Transcription
Su, B. G., & Henley, M. J. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.795743 · Cited by 25 · see citing works
Protein Haptenation and Its Role in Allergy
Aleksić, M., & Meng, X. (2024) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.4c00062 · Cited by 24 · see citing works
Expedited SARS‐CoV‐2 Main Protease Inhibitor Discovery through Modular ‘Direct‐to‐Biology’ Screening
Wilders, H., Biggs, G. S., Rowe, S. M., Cawood, E. E., Riziotis, I. G., Rendina, A. R., Grant, E. K., Pettinger, J., Fallon, D. J., Skehel, M. J., et al. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202418314 · Cited by 25 · see citing works
A manifesto for Alzheimer’s disease drug discovery in the era of disease-modifying therapies
Hering, H., Bussière, T., Liu, C., Glajch, K. E., Weihofen, A., Grogan, J. L., & Walsh, D. M. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00872-7 · Cited by 26 · see citing works
Ensemble Docking for Intrinsically Disordered Proteins
Dhar, A., Sisk, T. R., & Robustelli, P. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c00370 · Cited by 23 · see citing works
Ai, M., Ma, H., He, J., Xu, F., Ming, Y., Ye, Z., Zheng, Q., Luo, D., Yang, K., Li, J., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116978 · Cited by 21 · see citing works
Dual-Inhibitors of N-Myc and AURKA as Potential Therapy for Neuroendocrine Prostate Cancer
Ton, A., Singh, K., Morin, H., Ban, F., Leblanc, E., Lee, J., Lallous, N., & Cherkasov, A. R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218277 · Cited by 21 · see citing works
Proteome-wide Ligand and Target Discovery by Using Strain-Enabled Cyclopropane Electrophiles
Liu, Y., Yu, Z., Li, P., Yang, T., Ding, K., Zhang, Z., Tan, Y., & Li, Z. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c04695 · Cited by 20 · see citing works
Targeting MYC: Multidimensional regulation and therapeutic strategies in oncology
Duan, Y., Liu, Z., Wang, Q., Zhang, J., Liu, J., Zhang, Z., & Li, C. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2024.101435 · Cited by 21 · see citing works
Jung, Y., Noda, N., Takaya, J., Abo, M., Toh, K., Tajiri, K., Cui, C., Zhou, L., Sato, S., & Uesugi, M. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.1c00824 · Cited by 20 · see citing works
Zhou, M., Boulos, J. C., Omer, E. A., Klauck, S. M., & Efferth, T. (2023) · Molecules · doi:10.3390/molecules28155658 · Cited by 18 · see citing works
Chemical Proteomics–Guided Discovery of Covalent Ligands for Cancer Proteins
Zhang, X., & Cravatt, B. F. (2024) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061421-041946 · Cited by 19 · see citing works
Ton, A.-T., Foo, J., Singh, K., Lee, J., Kalyta, A., Morin, H., Perez, C., Ban, F., Leblanc, E., Lallous, N., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052588 · Cited by 17 · see citing works
“For example, compound EN4 was recently designed as a covalent ligand targeting the Cys171 residue within the intrinsically disordered region of Myc [16].”
BackgroundČermáková, K., Veverka, V., & Hodges, H. C. (2023) · Biochemical Society Transactions · doi:10.1042/bst20220342 · Cited by 17 · see citing works
Chai, X., Tao, Q., & Li, L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146901 · Cited by 18 · see citing works
Selectivity aspects of activity-based (chemical) probes
Heinzlmeir, S., & Müller, S. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.10.021 · Cited by 17 · see citing works
Rosen, H. T., Li, K., Stieger, C. E., Li, E. L., Currier, B., Brittain, S. M., Garcia, F. J., Beard, D. C., Jones, M. D., Haenni‐Holzinger, S., et al. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202508518 · Cited by 15 · see citing works
Self-citationRuprecht, B., Wei, L., Zheng, L., Bodea, S., Mo, X., Maschberger, M., Stoehr, G., Hahne, H., Cornella‐Taracido, I., & Chi, A. (2022) · Cell chemical biology · doi:10.1016/j.chembiol.2022.10.008 · Cited by 15 · see citing works
Small-Molecule Approaches to Target Transcription Factors
Cui, H., Stilgenbauer, M., & Koehler, A. N. (2024) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-062722-012209 · Cited by 16 · see citing works
Ellenbroek, B. D., Kahler, J. P., Arella, D., Lin, C., Jespers, W., Züger, E. A.-K., Drukker, M., & Pomplun, S. J. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202416082 · Cited by 14 · see citing works
Covalent Destabilizing Degrader of AR and AR-V7 in Androgen-Independent Prostate Cancer Cells
Zammit, C. M., Nadel, C. M., Lin, Y. Q., Koirala, S., Ahani, E., Potts, P. R., & Nomura, D. K. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c02801 · Cited by 13 · see citing works
Self-citationYang, L., Du, Y.-E., Liao, F., Huang, T., Liu, Y., Liu, J., Wang, C., Zhan, Z., Cao, Y., Wang, Z., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116486 · Cited by 13 · see citing works
Zhao, C., Zhao, F., Yang, L., Wang, Y., Wang, H., Fang, F., Zuo, H., Li, Z., He, G., Zhan, W., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00272 · Cited by 13 · see citing works
Proteomimetic Strategy for the Modulation of Intrinsically Disordered Protein MYC
Nguyễn, T. T., Hong, S. H., & Arora, P. S. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.4c18144 · Cited by 12 · see citing works
Functional screen identifies RBM42 as a mediator of oncogenic mRNA translation specificity
Kovalski, J. R., Sarioglu, G., Subramanyam, V., Hernandez, G. A., Rademaker, G., Osés-Prieto, J. A., Slota, M. J., Mohan, N., Yiakis, K., Liu, I., et al. (2025) · Nature Cell Biology · doi:10.1038/s41556-024-01604-7 · Cited by 12 · see citing works
Zhang, Q., Cui, K., Kong, Y., Yu, J., Luo, Z., Yang, X., Gong, L., Xie, Y., Lin, J., Liu, C., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115327 · Cited by 12 · see citing works
Rothweiler, E. M., Brennan, P. E., & Huber, K. (2022) · Biological Chemistry · doi:10.1515/hsz-2021-0396 · Cited by 12 · see citing works
Cai, M., Zheng, F., Ren, Y.-Z., Zhen, C., Fu, D., Song, X., Li, Q., Qu, Y., Chen, Z., & Zhao, S. (2025) · Research · doi:10.34133/research.0791 · Cited by 12 · see citing works
Henley, M. J., Doyle, S. K., & Koehler, A. N. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2020.12.014 · Cited by 11 · see citing works
Modulation of iron metabolism by new chemicals interacting with the iron regulatory system
Tsuji, Y., Ninomiya‐Tsuji, J., Shen, M. Y. F., & DiFrancesco, B. R. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103444 · Cited by 11 · see citing works
Taming transcription factors with TRAFTACs
Ng, C. S. C., & Banik, S. M. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.04.016 · Cited by 11 · see citing works
Ma, T. P., Izrael-Tomasevic, A., Mroue, R. M., Budayeva, H. G., Malhotra, S., Raisner, R. M., Evangelista, M., Rose, C. M., Kirkpatrick, D. S., & Yu, K. (2023) · Journal of Proteome Research · doi:10.1021/acs.jproteome.2c00703 · Cited by 10 · see citing works
Peng, Q., & Weerapana, E. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.11.010 · Cited by 9 · see citing works
Natural product-inspired molecules for covalent inhibition of SHP2 tyrosine phosphatase
Liang, W., Krabill, A. D., Gallagher, K. S., Muli, C. S., Qu, Z., Trader, D. J., Zhang, Z., & Dai, M. (2024) · Tetrahedron · doi:10.1016/j.tet.2024.133918 · Cited by 9 · see citing works
Comprehensive Mapping of Electrophilic Small Molecule-Protein Interactions in Human CellsPreprint
Cravatt, B. F., Njomen, E., Hayward, R., DeMeester, K. E., Ogasawara, D., Dix, M. M., Nguyen, T., Ashby, P., Simon, G. M., Schreiber, S. L., et al. (2023) · ChemRxiv · doi:10.26434/chemrxiv-2023-s446n · Cited by 9 · see citing works
Julio, A. R., Shikwana, F., Truong, C. C., Burton, N. R., Dominguez, E. R., Turmon, A. C., Cao, J. X., & Backus, K. M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.30.564067 · Cited by 8 · see citing works
Degrons and degradation signals beyond short linear motifs
Wang, B., & Zheng, N. (2025) · Nature Chemical Biology · doi:10.1038/s41589-025-02056-2 · Cited by 8 · see citing works
The covalent docking software landscape: features and applications in drug design
Singh, N., Vayer, P., & Villoutreix, B. O. (2025) · Briefings in Bioinformatics · doi:10.1093/bib/bbaf697 · Cited by 8 · see citing works
Palmitic acid activates c-Myc via dual palmitoylation-dependent pathways to promote colon cancer
Du, W., Zhang, J., Wang, Y., Li, M., Cao, J., Yang, B., He, Q., Shao, X., & Ying, M. (2026) · Cell Discovery · doi:10.1038/s41421-026-00869-6 · Cited by 8 · see citing works
A Simplified and Ultrafast Pipeline for Site-Specific Quantitative Chemical Proteomics
Xiao, W., Chen, Y., Zhang, J., Guo, Z., Hu, Y., Yang, F., & Wang, C. (2023) · Journal of Proteome Research · doi:10.1021/acs.jproteome.3c00179 · Cited by 8 · see citing works
Short circuit: Transcription factor addiction as a growing vulnerability in cancer
Davies, M., Boyce, M., & Conway, E. (2024) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2024.102948 · Cited by 8 · see citing works
Hu, X., Zhu, H., Meng, Q.-F., He, X., Shen, Y., Xu, Y., Zhou, Z., Pan, Y., Xu, X., & Rao, L. (2026) · Advanced Materials · doi:10.1002/adma.202523584 · Cited by 7 · see citing works
Inhibitors of the Transactivation Domain of Androgen Receptor as a Therapy for Prostate Cancer
Obst, J. K., Tien, A. H., Setiawan, J., Deneault, L. F., & Sadar, M. D. (2024) · Steroids · doi:10.1016/j.steroids.2024.109482 · Cited by 7 · see citing works
Conditional Covalent Lethality Driven by Oncometabolite Accumulation
Perez, M., Nance, K. D., Bak, D. W., Gamage, S. T., Najera, S. S., Conte, A. N., Linehan, W. M., Weerapana, E., & Meier, J. L. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.2c00384 · Cited by 6 · see citing works
Munugoda, U., Gilpatrick, S. T., Das, D., Parkin, S., Miller, A., & Awuah, S. G. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202516331 · Cited by 6 · see citing works
Intrinsically disordered proteins and liquid–liquid phase separation in drug discovery
Deka, N., Nag, N., & Tripathi, T. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104603 · Cited by 7 · see citing works
Bielskutė, S., Mateos, B., Awawdy, M., Garcia‐Cabau, C., Niskanen, H., Sánchez, C., Bracaglia, L., Pierattelli, R., Felli, I. C., Frigolé‐Vivas, M., et al. (2026) · Science Advances · doi:10.1126/sciadv.adz7400 · Cited by 6 · see citing works
Shikwana, F., Heydari, B. S., Ofori, S., Truong, C. C., Turmon, A. C., Darrouj, J., Holoidovsky, L., Gustafson, J. L., & Backus, K. M. (2024) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2024.100898 · Cited by 6 · see citing works
- Authors
- Boike, L., Cioffi, A. G., Majewski, F. C., Co, J., Henning, N. J., Jones, M. D., Liu, G., McKenna, J. M., Tallarico, J. A., Schirle, M., & Nomura, D. K.
- Affiliations
- University of California, Berkeley (US)
- Innovative Genomics Institute (US)
- Corresponding author
- Nomura, Daniel K.
- ORCID
- Venue
- Cell Chemical Biology
- Publisher
- Elsevier BV
- Published
- 2021-01
- Volume
- 28
- Issue
- 1
- Pages
- 4-13.e17
- ISSN
- 2451-9448 (ISSN-L)
- 2451-9456
- PMC
- PMC7854864
- OpenAlex
- W3089235055
- Cited by
- 154
- References
- 35
- Citations by year
- 2026: 25 · 2025: 39 · 2024: 29 · 2023: 17 · 2022: 20 · 2021: 22 · 2020: 1
- FWCI
- 4.81
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell chemical biology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health
- Mark Foundation For Cancer Research
- Novartis Institutes for BioMedical Research
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Physical Sciences › Chemistry › Organic Chemistry › Click Chemistry and Applications
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chemical Synthesis and Analysis
- Keywords
- c-Myc, intrinsically disordered proteins, covalent ligands, protein thermal stability, structure-activity relationship, MYC inhibitors, carcinogenesis
- MeSH terms
- Cells, Cultured, Cysteine, Dose-Response Relationship, Drug, Humans, Ligands, Molecular Structure, Proto-Oncogene Proteins c-myc
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
